Cell Pathways Aptosyn
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA issued a "not approvable" letter Sept. 25 for exisulind in treatment and prevention of familial adenomatous polyposis. The company intends to amend the NDA, which has been under priority review since its August 1999 submission, and expects a "possible requirement for additional clinical data